Abstract
Background Multiple sclerosis is a chronic demyelinating disorder of the central nervous system that is categorized as an immune-mediated inflammatory disease. This study aimed to systematically review the cost-benefit and cost-effectiveness of relapsing-remitting drugs for multiple sclerosis.
Methods To find related research and articles, articles published in Iranian and international databases by using a combination of MeSH (Medical Subject Headings) terms and based on inclusion and exclusion criteria were searched and reviewed. We included studies that addressed interventions, ICER, per QALY, and those which were published in a journal for different methods of infertility treatment, or a major general journal till 2019.
Results Out of 1,360 records found, finally, 21 records were included in the research. Ten articles were published in the European continent, six articles in the Americ continent, and finally, five articles in the Asia continent. The most common limitations of published economic evaluation studies were in methodology or presentation of incremental analyses, sensitivity analyses, and discounts. The lowest and highest numerical value of outcome measures were -1,623,918 and 2,297,141.53, resprectively. Furthermore, the lowest and highest numerical value of the cost of disease-modifying drugs of RRMS were $180.67, and $1474840.19, resprectively.
Conclusions Based on the results of all studies, it can be concluded that for the treatment of patients with AF, care-oriented strategies should be preferred to drug strategies. Also, among the drug strategies with different prescribing methods, oral disease-modifying drugs of RRMS should be preferred to injectable drugs and intravenous infusions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript